Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.
– Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placebo –– More than 40% o.
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young.
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.